Not provided
Not provided
Not provided
Not provided
Not provided
Business Decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective is to demonstrate the safety and effectiveness of the Axys EX rotational atherectomy system in subjects with peripheral arterial disease who have de novo or non-stented restenotic obstructive lesions in the peripheral vasculature of the lower limbs.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Axys EX device | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Axys EX device | Device | Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed |
|
| Measure | Description | Time Frame |
|---|---|---|
| Primary Effectiveness | Change in percent stenosis in the treatment vessel. Percent stenosis is defined as native vessel diameter as measured at the narrowest point of the lesion divided by the estimated native vessel diameter at that location. | During procedure |
| Primary Safety | Major Adverse Events (MAEs) at 30 Days post-procedure defined as freedom from clinically-driven target lesion revascularization (CD-TLR), major unplanned amputation of the treated limb, or all-cause mortality. | 30-Days |
| Measure | Description | Time Frame |
|---|---|---|
| Technical Success | Defined as the ability of the Axys EX device to successfully traverse/cross the entire intended length of the target lesion | During Procedure |
| Procedural Success | Defined as ≤ 30% residual stenosis following use of the Axys EX device and adjunctive therapy as measured by angiography and determined by the angiographic core laboratory |
Not provided
General Inclusion Criteria:
Rutherford Clinical Category (RCC) Score of 2 - 5
Willing and capable of complying with all follow-up evaluations at the specified times
Age ≥ 18 years old
Provides written informed consent prior to study specific procedures
Completed Ankle/Brachial Index (ABI) (or Toe/Brachial Index [TBI]) prior to index procedure (up to 60 days prior)
Angiographic Inclusion Criteria:
Evidence of ≥ 70% stenosis or occlusion in the peripheral vasculature of the target vessel, confirmed by angiography
Target lesion present in a single limb that consists of a single de novo or non-stented restenotic lesion, or qualifies as a tandem or combination lesion per the definitions below:
Exchangeable guidewire must cross target lesion within the lumen
Total target lesion length is ≥ 20 mm and ≤ 200mm
Reference vessel diameter (RVD) is ≥ 2.0 mm and ≤ 5.0 mm
Identifiable distal target vessel which upon completion of the intervention is anticipated to provide reconstitution of blood flow to the foot. Angiographic evidence of adequate distal runoff through the foot (at least one native calf vessel [posterior tibial, anterior tibial, or peroneal artery] is patent, defined as < 50% stenosed)
Multiple lesions in the target limb (including the target lesion and non-target lesions) may be treated if all of the following applies:
General Exclusion Criteria:
Has one or more of the contraindications listed in the Axys EX Rotational Atherectomy System's IFU
Contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs, or any other drug anticipated to be used
Hypersensitivity to contrast material that cannot be adequately pretreated
Known uncontrollable hypercoagulable condition or refuses blood transfusion
Life expectancy of less than 12 months
Surgical (requiring hospitalization) or endovascular intervention of the target limb within 30 days prior to the index procedure
Planned surgical intervention or endovascular procedure within 30 days after the index procedure
Currently participating in an investigational drug or another device study that may clinically interfere with the study endpoints
Other co-morbid condition(s) that in the judgment of the physician precludes safe percutaneous intervention
If a previous peripheral bypass affecting the target limb is present, the bypass must be patent and the target lesion cannot be present in the peripheral bypass artery
Impaired renal function (defined as GFR < 30 mL/min) or on dialysis
Recent myocardial infarction or stroke ≤ 30 days prior to the index procedure
Previous or planned amputation above the metatarsal line on the target limb
Patient belongs to a vulnerable population per investigator's judgment or patient has any kind of disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures. Patient must be able to consent for themselves
Patient is pregnant (female patients of child-bearing potential must have a pregnancy test done within 7 days prior to the index procedure)
Angiographic Exclusion Criteria:
Noted thrombus at the point of the intended target lesion
In-stent restenosis of the target lesion
Aneurysmal target vessel
Hemodynamic significant stenosis or occlusion of inflow tract that has not been revascularized prior to treatment of the target vessel
Perforation, flow limiting dissection or other injury of the target vessel requiring surgical intervention prior to enrollment
Disease that precludes safe advancement of the Axys EX device to the target lesion
Need to treat a lesion distal to the target index lesion
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ravish Sachar, MD FACC | North Carolina Heart and Vascular | Principal Investigator |
| Brian DeRubertis, MD FACS | University of California, Los Angeles | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D058729 | Peripheral Arterial Disease |
| D016491 | Peripheral Vascular Diseases |
| D000089802 | Chronic Limb-Threatening Ischemia |
| D050197 | Atherosclerosis |
| D001161 | Arteriosclerosis |
| D014652 | Vascular Diseases |
| D001157 | Arterial Occlusive Diseases |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| During Procedure |
| Amputation-Free Survival | Defined as freedom from a major, unplanned amputation of the target limb through the 12 month visit | 12-Months |
| Major Adverse Events (MAEs) | Defined as freedom from clinically-driven target vessel revascularization (CD-TVR), major unplanned amputation of the treated limb, thrombosis at the target lesion site, or all-cause mortality | 12-Months |
| Rate of Target Lesion Revascularization (TLR) | Any re-intervention at the target lesion | 6 and 12-Months |
| Rate of Target Vessel Revascularization (TVR) | Any re-intervention within the target vessel | 6 and 12-Months |
| Provisional Stent Rate | During Procedure |
| Flow Limiting Dissection | Target lesion flow limiting dissection (D or greater) rate after adjunctive therapy | During Procedure |
| Primary Patency as determined by Duplex Ultrasound (DUS) |
| 6 and 12-Months |
| Quality of Life Assessment | EQ-5D questionnaire | 30-Days, 6 and 12-Months |
| Walking Distance | 6-Minute Walking Test | 30-Days, 6 and 12-Months |
| Walking Capacity | Walking Impairment Questionnaire (WIQ) | 30-Days, 6 and 12-Months |
| Ankle/brachial index (ABI) or toe/brachial index (TBI) | 30-Days, 6 and 12-Months |
| Rutherford clinical category (RCC) | 30-Days, 6 and 12-Months |
| Distal Embolization in Target Limb | Clinically significant distal embolization in target limb within 30 days defined as distal embolization requiring treatment by mechanical or pharmacologic means (other than a vasodilator) (adjudicated by a Clinical Events Committee) | 30-Days |
| Major Vessel Perforation | requiring surgical or endovascular repair within 30 days (adjudicated by a Clinical Events Committee) 6. | 30-Days |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D007511 | Ischemia |